How respiratory virus vaccines protect people in Cleveland across health and social backgrounds
Official title: RFA-IP-22-004, CORVETS - Cleveland Ohio Respiratory Viruses Vaccines Effectiveness across Traditional Risk Factors and Social Determinants of Health
Funded at University Hospitals of Cleveland · NIH-11423354 · Data updated 2026-11-12
This project is looking at how well flu, COVID-19, and other respiratory virus vaccines keep children and adults from getting sick when they visit outpatient clinics in Cleveland.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University Hospitals of Cleveland NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 30, 2022 |
| Project end | September 29, 2027 |
| Funding year | 2025 |
| Award (this year) | $200,000 |
| NIH project number | 6U01IP001181-04M001 |
| Project ID | NIH-11423354 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children and adults in the Cleveland area who seek outpatient care for flu-like or COVID-like symptoms, including patients at University Hospitals, affiliated clinics, and the Cleveland VA.
✕Less likely to help
People without symptoms, those hospitalized for severe respiratory illness, or individuals living outside the study's Cleveland-area clinics are unlikely to participate or directly benefit.
What this research studies
If you join, the team will enroll you when you go to an outpatient clinic with symptoms of an acute respiratory infection and add your de-identified health information to a study repository. They plan to enroll at least 1,000 patients each year from University Hospitals, Case Western Reserve, and the Cleveland VA to create a racially and socially diverse sample. Researchers will collect respiratory samples and use molecular testing and viral genome sequencing to identify the specific viruses and variants causing illness. They will link those lab results to your vaccination history, medical risk factors, and household or community social factors to see how protection varies across people.
Why it matters
Potential benefit: Findings could help tailor vaccine recommendations and outreach so people and communities at higher risk get better protection.
How similar studies have gone: Similar vaccine-effectiveness networks using test-negative designs and genomic sequencing have successfully tracked vaccine performance and variant impacts, so this approach builds on proven methods.
Where this research is happening
-
University Hospitals of Cleveland
Cleveland, United States Active
Researchers
- Principal investigator: Saade, Elie — University Hospitals of Cleveland
- Study coordinator: Saade, Elie
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
ALS risk factors in a long-term ALS study
A long-term ALS study is looking at which factors may influence disease risk and progression in people living with ALS.
-
Understanding how work exposures and genes influence ALS risk
A study is building a long-term group of people at higher risk for ALS to see how their jobs, exposures at work, and genes together affect if and when the disease might develop.
-
P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetic, behavior, and vascular data
Aims to predict Alzheimer’s disease risk in middle-aged South Asians by combining genetic, lifestyle, and vascular information to catch early changes before dementia develops.
-
P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetics, behavior, and vascular data
Aimed at people 21 and older, this project looks at how biology, behavior, and blood vessel health together may signal the early risk of Alzheimer’s disease and related dementias in South Asians.
-
Understanding how risk factors affect progression of cirrhosis and response to statins in patients with cirrhosis
This project follows people with cirrhosis to see what factors speed up their liver disease and whether statin medicines help prevent worsening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.